Skip to main content

Table 1 Gestational age and maternal malaria infection status at delivery

From: Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study

 

AL

ASAQ

MQAS

DHAPQ

p-valuea

N

 

N

 

N

 

N

  

Maternal age median (IQR)

881

21 (18–26)

842c

22 (19–27)

850c

22 (19–27)

855

20 (18–25)

0.67

Gestational age (week) median (IQR)

804

38 (36–38)

729

38 (38–40)

733

38 (36–40)

709

38 (36–38)

0.30

Gravidity n (%)

880

 

842

 

850

 

855

 

0.55

 1st pregnancy

 

319 (36.3)

 

315 (37.4)

 

278 (32.7)

 

343 (40.1)

 

 2nd pregnancy

 

204 (23.2)

 

187 (22.2)

 

201 (23.7)

 

216 (25.3)

 

 3rd or more

 

357 (40.6)

 

340 (40.4)

 

371 (43.7)

 

296 (34.6)

 

Malaria prevalence (peripheral blood) n (%)

829

120 (14.5)

756

95 (12.6)

752

123 (16.4)

748

75 (10.0)

0.21

Parasite density; median (IQR)

120

1560 (440–6804)

95

1800 (320–8220)

123

1729 (561–9000)

75

2320 (480–8960)

0.09

 % ≤ 2000/µL (n)

 

55.0 (66)

 

53.7 (51)

 

52.0 (64)

 

46.7 (35)

 

 % > 2000/µL (n)

 

45.0 (54)

 

46.3 (44)

 

48.0 (59)

 

53.3 (40)

 

Gametocyte carriage n (%)

829

3 (0.4)

756

4 (0.5)

752

4 (0.5)

748

2 (0.3)

0.89

Maternal Hb median (IQR)

828

11.2 (10.1–12.2)

757

11.5 (10.4–12.4)

752

11.3 (10.3–12.3)

749

11.2 (10.3–12.2)

0.30

Placenta Malaria n (%)b

711

 

655

 

674

 

664

  

 Acute infection

 

7 (1.0)

 

14 (2.1)

 

13 (1.9)

 

11 (1.7)

 

 Chronic infection

 

191 (26.9)

 

168 (25.6)

 

177 (26.3)

 

171 (25.8)

 

 Past infection

 

444 (62.4)

 

382 (58.3)

 

398 (59.1)

 

409 (61.6)

 

 No infection

 

69 (9.7)

 

91 (13.9)

 

86 (12.8)

 

73 (11.0)

 
  1. aAdjusted by country
  2. bThe proportion of current (acute and chronic) and past infection vs. no infection, adjusted for country, p = 0.47. Proportion of acute and chronic infection vs. past or no infection, adjusted for country p = 0.52
  3. cOne woman randomized to the ASAQ group was treated with MQAS; in the safety analysis this woman was included in the MQAS group